JP2017505316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505316A5 JP2017505316A5 JP2016549493A JP2016549493A JP2017505316A5 JP 2017505316 A5 JP2017505316 A5 JP 2017505316A5 JP 2016549493 A JP2016549493 A JP 2016549493A JP 2016549493 A JP2016549493 A JP 2016549493A JP 2017505316 A5 JP2017505316 A5 JP 2017505316A5
- Authority
- JP
- Japan
- Prior art keywords
- antipsychotic drug
- vmat2 inhibitor
- effective amount
- therapeutically effective
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000561 anti-psychotic effect Effects 0.000 claims description 103
- 239000003814 drug Substances 0.000 claims description 101
- 229940079593 drug Drugs 0.000 claims description 100
- 239000003112 inhibitor Substances 0.000 claims description 68
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 16
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000024714 major depressive disease Diseases 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 12
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims description 8
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 8
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 8
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 8
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 8
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 8
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004372 aripiprazole Drugs 0.000 claims description 8
- 229960005245 asenapine Drugs 0.000 claims description 8
- 229960004170 clozapine Drugs 0.000 claims description 8
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 8
- 229960002690 fluphenazine Drugs 0.000 claims description 8
- 229960003878 haloperidol Drugs 0.000 claims description 8
- 229960003162 iloperidone Drugs 0.000 claims description 8
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 8
- 229960000423 loxapine Drugs 0.000 claims description 8
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 8
- 229960005017 olanzapine Drugs 0.000 claims description 8
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 8
- 229960001057 paliperidone Drugs 0.000 claims description 8
- 229960000762 perphenazine Drugs 0.000 claims description 8
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 8
- 229960003634 pimozide Drugs 0.000 claims description 8
- 229960004431 quetiapine Drugs 0.000 claims description 8
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 8
- 229960001534 risperidone Drugs 0.000 claims description 8
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 8
- 229960004940 sulpiride Drugs 0.000 claims description 8
- 229960002784 thioridazine Drugs 0.000 claims description 8
- 229960000607 ziprasidone Drugs 0.000 claims description 8
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 8
- 206010003805 Autism Diseases 0.000 claims description 6
- 208000020706 Autistic disease Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000027534 Emotional disease Diseases 0.000 claims description 5
- 230000000698 schizophrenic effect Effects 0.000 claims description 5
- 239000003196 psychodysleptic agent Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004938 molindone Drugs 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims 5
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 claims 4
- MLAYZCMWRNQKQX-UHFFFAOYSA-N 2-hydroxy-1h-isoquinoline Chemical compound C1=CC=C2C=CN(O)CC2=C1 MLAYZCMWRNQKQX-UHFFFAOYSA-N 0.000 claims 2
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 229960002324 trifluoperazine Drugs 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical group C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 4
- MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- -1 isoquinolin-2-yl Chemical group 0.000 description 4
- 229960005333 tetrabenazine Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937223P | 2014-02-07 | 2014-02-07 | |
| US61/937,223 | 2014-02-07 | ||
| PCT/US2015/014893 WO2015120317A1 (en) | 2014-02-07 | 2015-02-06 | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087459A Division JP2019116515A (ja) | 2014-02-07 | 2019-05-07 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505316A JP2017505316A (ja) | 2017-02-16 |
| JP2017505316A5 true JP2017505316A5 (cg-RX-API-DMAC7.html) | 2018-03-22 |
| JP6718376B2 JP6718376B2 (ja) | 2020-07-08 |
Family
ID=52589782
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549493A Active JP6718376B2 (ja) | 2014-02-07 | 2015-02-06 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
| JP2019087459A Withdrawn JP2019116515A (ja) | 2014-02-07 | 2019-05-07 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
| JP2021032320A Pending JP2021080294A (ja) | 2014-02-07 | 2021-03-02 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
| JP2023195803A Pending JP2024003253A (ja) | 2014-02-07 | 2023-11-17 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087459A Withdrawn JP2019116515A (ja) | 2014-02-07 | 2019-05-07 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
| JP2021032320A Pending JP2021080294A (ja) | 2014-02-07 | 2021-03-02 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
| JP2023195803A Pending JP2024003253A (ja) | 2014-02-07 | 2023-11-17 | 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9782398B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4049681A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6718376B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102328058B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113413385A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015213778B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2938581C (cg-RX-API-DMAC7.html) |
| IL (1) | IL247127B (cg-RX-API-DMAC7.html) |
| MX (1) | MX378664B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ760790A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2021128797A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015120317A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3936130T3 (da) * | 2014-05-06 | 2024-03-25 | Neurocrine Biosciences Inc | Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser |
| AU2016215033B2 (en) | 2015-02-06 | 2020-06-25 | Neurocrine Biosciences, Inc. | (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| HRP20240304T1 (hr) | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| ES2811048T3 (es) * | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| EP4400171A3 (en) * | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| WO2018115001A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| EP3733666B1 (en) | 2017-12-26 | 2022-09-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof |
| EP3784237B1 (en) | 2018-04-25 | 2023-11-01 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| CN116726169A (zh) * | 2018-05-04 | 2023-09-12 | 韩国原子力医学院 | 包含阿立哌唑作为活性成分的辐射敏感性增强组合物 |
| WO2019241555A1 (en) | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| WO2020188551A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for treating autism spectrum disorder and associated disorders |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| JP2024524324A (ja) * | 2021-06-30 | 2024-07-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症のアドオン処置において使用するためのバルベナジン |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| JPS57209225A (en) * | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| WO2000024399A1 (en) * | 1998-10-23 | 2000-05-04 | Sepracor Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| EP1855677B1 (en) * | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US8039627B2 (en) * | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2463452A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| HUE038158T2 (hu) | 2008-09-18 | 2018-09-28 | Auspex Pharmaceuticals Inc | Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2015
- 2015-02-06 CN CN202110257547.XA patent/CN113413385A/zh active Pending
- 2015-02-06 JP JP2016549493A patent/JP6718376B2/ja active Active
- 2015-02-06 WO PCT/US2015/014893 patent/WO2015120317A1/en not_active Ceased
- 2015-02-06 US US15/116,786 patent/US9782398B2/en active Active
- 2015-02-06 CA CA2938581A patent/CA2938581C/en active Active
- 2015-02-06 NZ NZ760790A patent/NZ760790A/en unknown
- 2015-02-06 RU RU2021128797A patent/RU2021128797A/ru unknown
- 2015-02-06 NZ NZ723107A patent/NZ723107A/en unknown
- 2015-02-06 CN CN201580009498.0A patent/CN106061506A/zh active Pending
- 2015-02-06 AU AU2015213778A patent/AU2015213778B2/en active Active
- 2015-02-06 EP EP21216409.9A patent/EP4049681A1/en active Pending
- 2015-02-06 RU RU2016135930A patent/RU2757221C2/ru active
- 2015-02-06 EP EP15706596.2A patent/EP3102239A1/en not_active Withdrawn
- 2015-02-06 MX MX2016010071A patent/MX378664B/es unknown
- 2015-02-06 CN CN202110257206.2A patent/CN113368110A/zh active Pending
- 2015-02-06 KR KR1020167024297A patent/KR102328058B1/ko active Active
-
2016
- 2016-08-04 IL IL247127A patent/IL247127B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/701,311 patent/US20180085364A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/248,855 patent/US20190381029A1/en not_active Abandoned
- 2019-05-07 JP JP2019087459A patent/JP2019116515A/ja not_active Withdrawn
-
2020
- 2020-03-13 US US16/817,723 patent/US20200206215A1/en not_active Abandoned
-
2021
- 2021-03-02 JP JP2021032320A patent/JP2021080294A/ja active Pending
-
2023
- 2023-11-17 JP JP2023195803A patent/JP2024003253A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505316A5 (cg-RX-API-DMAC7.html) | ||
| RU2016135930A (ru) | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение | |
| JP6812360B2 (ja) | 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 | |
| JP2017514850A5 (cg-RX-API-DMAC7.html) | ||
| PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| CU20170154A7 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk | |
| JP2016503030A5 (cg-RX-API-DMAC7.html) | ||
| JP2013537184A (ja) | 新規な使用 | |
| JP2017503842A5 (cg-RX-API-DMAC7.html) | ||
| ES2668380T3 (es) | Moduladores de receptores de andrógenos y sus usos | |
| JP2015537003A5 (cg-RX-API-DMAC7.html) | ||
| UA117260C2 (uk) | Лікарський препарат з відстроченим вивільненням | |
| ECSP11011403A (es) | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| JP2017513925A (ja) | 徐放性ブプレノルフィン溶液 | |
| JP2015506359A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells | |
| FI3970707T3 (fi) | Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon | |
| KR101780739B1 (ko) | 활성성분-함유 필름 코팅층을 포함하는 복합제제 | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| GT201300144A (es) | Composiciones farmaceuticas | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| MX2022004197A (es) | Inhibidores del factor d del complemento para administracion oral. |